News Avalyn seeks $300m from its IPO Pulmonary fibrosis drug developer Avalyn prices its IPO at around $300m, as Seaport and Hemab both target $180m-plus from their listings.
News Alamar, Hemab, Kailera, and Seaport advance IPOs The last few days have seen a flurry of biotech IPO news, with Alamar, Hemab, Kailera, and Seaport all pushing for Nasdaq listings.
News Electra banks $183m for sHLH drug, and other biofinancings Our round-up of recent biotech financings includes a big round for Electra, with Hemab, Zag Bio, Elevara, Expedition, and Curve also adding new funds.
News Judge backs Lilly in Novo lawsuit over weight-loss drug ads A US judge has blocked Novo's request for an injunction on Eli Lilly's advertising for weight-loss and diabetes drugs Mounjaro and Zepbound.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
